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Interleukin 4 (IL-4)/B cell stimulatory factor 1 is aT cell-derived lymphokine
that has effects on virtually all cells of hematopoietic origin . In particular, it
strikingly enhances the secretion of IgGI and IgE in vitro and of IgE in vivo (1-
10) . IL-4 acts on cells that lack surface IgG to cause IgG1 production (1, 11),
strongly suggesting that it promotes Ig class switching rather than the selective
expansion of previously switched cells .
In the course of studies using rIL-4 concentrations substantially higher than
those previously reported, we observed a number of new and interesting prop-
erties of IL-4 in the promotion of IgGI and IgE production by murine B cells
stimulated by bacterial LPS in vitro . We report here that the IL-4 dose/IgGI
response curve is bimodal with peaks at 100 and 10,000 U IL-4/ml and with a
nadir at 600 U/ml . Furthermore, very substantial amounts of IgE (^-1 ug from
2 x 104 cells initially cultured) are produced by B cells stimulated with LPS and
10,000 U/ml of IL-4 . Finally, marked suppression of IgM and IgG2a as well as
IgG3 and IgG2b (12) occurs with IL-4 concentrations of ^-600 U/ml . These
stimulatory and suppressive activities cannot be accounted for by changes in
viable cell yields or [sH]thymidine incorporation and can be completely reversed
by a monoclonal anti-IL-4 antibody . We further demonstratethat IL-4 acts both
early and late in the culture period with markedly different effects on IgGI and
IgE secretion . Our results indicate that IL-4 differentially regulates IgGI and
IgE secretion .
Materials and Methods
Animals .
￿
Pathogen-free female DBA/2 mice, 8-12 wk old, were obtained from DCT
Animal Program, National Cancer Institute (Frederick, MD).
Culture Medium (RPMI).
￿
RPMI 1640 (Biofluids, Inc., Rockville, MD) supplemented
with 10% FCS (HyClone Laboratories, Inc ., Logan, UT), 2 MM L-glutamine, 0.05 mM
2-ME, 50 ug/ml penicillin, and 50 /Ag/ml streptomycin was used for culturing cells.
Reagents andMonoclonal Antibodies.
￿
Percoll was obtained from Pharmacia Fine Chem-
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icals, (Piscataway, NJ). LPS W extracted from Escherichia coli 0111 :114 was obtained from
Difco Laboratories, Inc . (Detroit, MI) and was used at 20 tug/ml in all experiments. rIL-
4, kindly provided by Immunex Corp., Seattle, WA, was obtained from a yeast expression
system using the alcohol dehydrogenase 2 promoter and the a-factor gene leader sequence
to direct synthesis and secretion . The material was used in the form of a yeast cell
supernatant that had an activity of 250,000 U/ml. Unitage was measured, by Immunex,
in an anti-IgM costimulation assay in which 1 U of activity was equal to 5 pg of purified
IL-4 (13) . Purified T cell-derived IL-4, kindly provided by Dr. Junichi Ohara of this
laboratory, was used in some experiments. This material was derived from EL-4 cells by
induction with PMA and was purified to homogeneity by affinity chromatography and
reverse-phase HPLC (14). Monoclonal rat IgGI anti-IL-4 antibody (IIBI1) (15) was
purified from ascitic fluid by ammonium sulfate precipitation, passage over a DEAE
cellulose column, followed by Sephadex G200 gel filtration. To remove any residual
mouse IgGI, the anti-IL-4 antibody preparation was adsorbed over a 20.10.9.1 column
(monoclonal mouse IgG2a [b allotype] anti-mouse IgGI [a allotype]) (16). Monoclonal rat
IgGI anti-NP antibody (J4.1) was a kind gift from Dr. R. Coffman from DNAX (Palo
Alto, CA) and was similarly purified from ascites and used as a control for 111111 .
Preparation ofB Cells.
￿
Enriched populations of B cells were obtained from spleen cells
from which T cells had been eliminated by the method of Leibson et al. (17). Small, dense
B cells were separated by the modified (18) discontinuous Percoll-gradient centrifugation
procedure of DeFranco et al. (19). Cells forming a band between 66 and 70% Percoll and
having a density of 1 .081-1 .086 g/ml were considered to be resting B cells and were used
in all experiments.
Cell Cultures.
￿
Functional assays were carried out in 96-well flat-bottom plates (Costar,
Cambridge, MA) in a 200-ul final volume. Plates were incubated at 37°C in a humidified
6% C02 atmosphere. DNA synthesis was determined by [sH]thymidine uptake (2 yCi/well ;
6.7 Ci/nmol ; 1 mCi = 37GBq; ICN K & K Laboratories Inc., Irvine, CA) over a 6-h
period. Cells were harvested onto glass filter paper and [sH]thymidine incorporation was
determined by liquid scintillation spectrometry. For preincubation experiments, resting
B cells were cultured in 25-cm2 tissue culture flasks (Corning Glass Works, Corning, NY)
at 2 .5 x 105 cells/ml in the presence of LPS and IL-4 (600 or 10,000 U/ml) for 48 h.
Cells were then washed three times in cold HBSS, counted, and replated into 96-well flat-
bottom plates (Costar) for further analysis.
Measurement ofIg Isotype Concentrations in Culture Supernatants.
￿
Ig isotype concentra-
tions were measured by an ELISA using Immulon 2, 96-well flat-bottomed ELISA plates
(Dynatech Laboratories, Inc ., Alexandria, VA) and has been described by us in detail
elsewhere (11). Briefly, a fluorescent product, generated from cleavage of 4-methyl
umbilliferyl phosphate (Sigma Chemical Co., St. Louis, MO) by specifically bound alkaline
phosphatase-conjugated antibodies, was quantitated on a fluorometer (Allergenetics, a
division of Axonics, Inc., Mountain View, CA). Fluorescence units were converted to Ig
concentrations by extrapolation from standard curves, determined using purified myeloma
proteins of known concentration. Each assay system showed no significant cross-reactivity
or interference from the concentration of other isotypes (IgM, IgD, IgG3, IgGI, IgG2b,
IgG2a, IgE, IgA) found in the culture supernatants. For some IgGI determinations in
which high concentrations of anti-IL-4 (111111) and anti-NP (J4.1) antibodies were
present in culture supernatants, ELISA wells were coated with the monoclonal anti-IgGI
antibody, 20 .10 .9.1 . The 11B 11 andJ4.1 preparations had been adsorbed on a 20.10 .9.1
column. After addition of culture supernatants and standards and washing, polyclonal
rabbit anti-mouse IgG I (20) was added followed by alkaline phosphatase goat anti-rabbit
IgG (21). In this assay, 1 mg/mI of either 111111 or J4.1 scored as 100 ng/ml of IgGI
(0 .01 %) which was too low to influence the measurements of IgG 1 concentrations in the
culture supernatants.
Results
IL-4 Causes Bimodal Stimulation of IgGI Production, Secretion ofLarge Amounts
of IgF,, and Profound Suppression of Other Ig Isotypes.
￿
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FIGURE 1 . IL-4 modulates Ig isotype secretion by
LPS-stimulated murine B cells. Purified, resting Bcells
were distributed into 96-well plates at 2 X IO' cells/0.2
ml and stimulated with 20 ug/ml LPS. Increasing
concentrations of IL-4 were added and Ig isotypes
were measured in culture supernatants by ELISA at
the end of 6 d.
were stimulated with LPS and increasing concentrations ofrIL-4. Production of
Ig of various isotypes was measured on the sixth day of culture. The IL-4
dose/IgGI response curve was strikingly bimodal (Fig. 1). IgGI levels peak at
IL-4 concentrations between 40 and 160 U/ml to levels of^"18.5ug/mlcompared
with 1 ug/ml in cells stimulated with LPS alone. However, with increasing IL-4
concentrations, IgG1 levels progressively decline reaching a nadir at -1,000
U/ml (3.0 Mg/ml). A further increase in IL-4 concentration to 10,000 U/ml
results in a progressive rise in the level of IgGI to 15.0 jAg/ml.
The amount ofIgE appearing in these cultures risesprogressively with increas-
ing IL-4 concentrations reaching a concentration of 4.2 ,ug/ml at 10,000 U/ml
compared with <0.001 ttg/ml in cells stimulated with LPS alone (Fig. 1). At IL-
4 concentrations at which IgG1 secretion reaches its first peak (40-160 U/ml),
IgE levels, although substantially above those obtained with LPS alone, are only
2% of maximal. No suppression of IgE production at intermediate IL-4 concen-
trations is observed. The amount of IL-4 needed for optimal IgE secretion is
similar to that required for the second peak for IgG1 production and is 100-fold
higher than that needed for the first peak of IgGI production.
As IL-4 concentrations are increased, IgM and IgG3 (Fig. 1) and IgG2b and
IgG2a production (Table I) show progressive, marked declines over amounts
obtained with LPS stimulation only. Significant degrees of suppression of these186
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TABLE I
IL-4 Suppresses IgG2b and IgG2a Secretion by
LPS-stimulated B Cells
Purified, resting B cells were distributed into 96-well plates at 2 X 104
cells/0.2 ml andstimulated with LPS (20Wg/ml). 100, 500, or 2,500 U/ml
IL-4 wasadded to selected wells andculture supernatants were removed
on day6 fordetermination ofIgG2bandIgG2aconcentrations by ELISA.
isotypes are generally seen at IL-4 levels at which the initial peak IgGI secretion
is obtained (40-160 U/ml). Maximal degrees ofsuppression, ranging from 95 to
98% for these isotypes, were observed at 300-600 U IL-4/ml. Concentrations
of IL-4 up to 10,000 U/ml fail to enhance either IgA or IgD secretion over the
undetectable levels seen with LPS stimulation only (data not shown).
We also studied Ig production by B cells stimulated with LPS and purified T
cell-derived IL-4, in concentrations from 10 to 1,000 U/ml. We observed both
the initial peak and nadir of IgG1 production, stimulation in IgE production,
and suppression of IgM, IgG3, IgG2b, and IgG2a (data not shown), confirming
that both recombinant and T cell-derived IL-4 have similar functions.
Anti-IL-4 Antibody Reverses Both the Enhancement and Suppression of Ig Isotype
Secretion by IL-4. Monoclonal anti-IL-4 antibody was used to assess whether the
dramatic changes in Ig isotype secretion induced by IL-4 in LPS-stimulated B
cell cultures was an effect of IL-4 itself and not of some possible contaminant.
An isotype-matched mAb (J4.1) was used as a control. The cells were stimulated
with LPS and 600 U/ml of IL-4, a concentration which yields a nadir in the
IgG1 response curve. Addition of increasing concentrations of anti-IL-4 Ab to
cultures stimulated with LPS and 600 U IL-4 initially produced a rise in IgGI
levels and then a progressive decline to levels similar to those obtained in cultures
to which LPS but no IL-4 had been added (Fig. 2). Addition ofJ4.1 had no
effect . This result indicates that both the first peak and the nadir in the IL-4
dose/IgGI response curve is due to IL-4 and not to some possible contaminant
in the IL-4 preparation.
The addition of 600 U IL-4/ml caused a 94% diminution in IgM secretion.
Addition of increasing amounts of anti-IL-4 produced a steady rise in IgM
concentrations approaching that observed in response to LPS alone indicating
that the suppressive effect of IL-4 on IgM production is also an effect of IL-4.
In a separate experiment, we evaluated the capacity ofanti-IL-4 to inhibit IgE
production in response to LPS and 10,000 U/ml of IL-4. Cells stimulated with
LPS only produced <0.001 hg/ml of IgE. Addition of 10,000 U IL-4/ml gave 4
jug IgE/ml . Addition of increasing amounts ofanti-IL-4 to these cultures caused
a progressive decline in IgE concentrations to 0.009 leg/ml whereas addition of
Treatment
Ig
IgG2b
ng/ml
concentration
IgG2a
LPS 950 70
LPS + IL-4 (100 U/ml) 550 50
LPS + IL-4 (500 U/ml) 55 6
LPS + IL-4 (2,500 U/ml) 20 6SNAPPER ET AL .
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FIGURE 2 . Anti-IL-4 antibody reverses the effect of
high concentrations ofIL-4 . Purified, restingB cellswere
distributed into 96-well plates at 2 X 10" cells/0.2 ml and
stimulated with 20 Feg/ml LPS and either 600 U/ml (for
IgM and IgGI) or 10,000 U/ml (for IgE) IL-4 . In addi-
tion, increasing amounts of either anti-IL-4 (I IB11) or
control anti-NP (J4.1) antibody were added (0.03-10
Fag/ml for IL-4 600 U/ml or 0.03-70 ug/ml for IL-4
10,000 U/ml) . Ig isotypes were measured in culture su-
pernatants by ELISA at theend of 6 d .
J4 .1 at similar concentrations had no effect (Fig . 2) . In this experiment, we also
measured IgGI production in response to 10,000 U/ml of IL-4, the concentra-
tion that causes the second peak of IgGI . Anti-IL-4 inhibited this response
whereasJ4.1 had no effect (data notshown) . These results indicate that even for
effects that require very large amounts of the IL-4 preparation, the active entity
is IL-4 .
Changes in Ig Isotype Secretion Induced by IL-4 Cannot Be Accountedfor by Changes
in Cell Yield or [3H]Thymidine Incorporation . Resting B cells were stimulated
with LPS ; IL-4 (125,600, and 10,000 U/ml) was added to selected wells . Viable
cell yields and [sH]thymidine incorporation were measured on each of days 2-6
and culture supernatants were tested for Ig isotype concentrations on day 6 . The
addition of IL-4 at 125 and 600 U/ml caused a modest suppression in viable cell
yields on day 3 and 4 (16-22% and 21%, respectively) and [sH]thymidine
incorporation (17-34% and 16-31%, respectively) over that observed with LPS
stimulation only (Fig. 3 and Table II). The greatest degree of suppression was
seen with 10,000 U/ml of IL-4 (44-63% for cell yield and 38-44% for [sH]-
thymidine incorporation) . Since IgM secretion was inhibited by 95% and IgG3
by 99% at an IL-4 concentration of 600 U/ml, this inhibition could not be
ascribed to generalized inhibition of cell growth or survival . Furthermore, IgGI188 DIFFERENTIAL REGULATION OF IgGI AND IgE SYNTHESIS
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FIGURE 3.
￿
IL-4 induces changes in viable cell yields and thymidine incorporation of LPS-
stimulated B cells. Purified, resting B cells were distributed into 96-well plates at 2 X 10'
cells/0.2 ml and stimulated with 20 ,iag/ml LPS. IL-4 (0 [01, 125 [0], 600 [0), or 10,000 [0]
U/ml)wasaddedto selected wells. On each ofdays 2-6, wellswere harvestedfordetermination
of viable cell yields and ['H]thymidine incorporation. In addition, culture supernatants were
removed at the end of 6 d for determination of Ig isotype concentrations by ELISA (Table
II).
Ig Isotype Concentrations as Shown by ELISA
Culturesupernatants were removed at theend of 6 d for determination of Ig isotype concentrations.
See Fig. 3 for details.
levels decreased from 28.1-5.1 jug/ml (82% suppression) as IL-4 was increased
from 125-600 U/ml, despite no change in cell yield or [3H]thymidine incorpo-
ration. Finally, the highest IgE levels (1 .9,ug/ml) andthe second IgGI peak (16.2
jug/ml) occurred at an IL-4 concentration of 10,000 U/ml where cell yield and
[3H]thymidine incorporation were at their lowest levels. Hence, the degree of
suppression observed for IgM, IgG3, and IgGl, and the level of enhancement
for IgE and the second rise in IgG1 cannot be explained simply by an overall
change in cell numbers or [3H]thymidine incorporation.
Short-term Exposure of B Cells to IL-4 Causes Maximal Production ofIgGI.
￿
B
cells were cultured with LPS and either 100 or 600 U/ml ofIL-4. To terminate
the action of the lymphokine, anti-IL-4 was added on various days of culture.
All supernatants were removed 6 d after the initiation ofculture for determina-
tion of Ig isotype concentrations. Addition of anti-IL-4 at the outset of culture
completely blocks the stimulation of IgGI (Fig. 4) and ofIgE and the inhibition
ofIgM (data not shown).
Delaying the addition of anti-IL-4 by 2 d results in IgGl production in
response to 100 U/ml of IL-4 equivalent to that obtained if IL-4 was present for
the entire culture period. By contrast, stimulating B cells with 600 U/ml of IL-
4 for only the first 2 d caused greater production of IgGI than was observed
with either 600 or 100 U/ml of IL-4 present for the entire culture (Fig. 4).
Treatment IL-4
U/ml
IgM
Ig
IgG3
concentration
IgGI
Ecg/ml
IgE
LPS 0 128.0 10.0 4.0 <001
LPS + IL-4 125 21 .2 1.3 28.1 0.12
LPS + IL-4 600 6.5 0.1 5.1 0.22
LPS + IL-4 10,000 7.0 0.1 16.2 1.9E
a
c
0 v
of
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DAY OF ANTI-IL-4 AB
ADDITION
FIGURE 4.
￿
Duration of IL-4 exposure influences levels of secreted IgGl . Purified, resting B
cells were distributed into 96-well plates at 2 X 104 cells/0.2 ml and stimulated with 20 Ag/ml
LPS. Either 100 (O)or 600 (") U/ml IL-4 wasadded at the beginningof culture. On each of
days 0-5, 20 jug/ml anti-IL-4 Ab was added to different wells (sufficient to completely
terminatetheaction of IL-4). Ig isotypes were measured in culture supernatants at the end of
6dby ELISA.
Indeed, the presence of 600 U/ml of IL-4 for the entire 6-d culture period
consistently leads to the lowest levels of IgGI in the bimodal response to the
lymphokine while 100 U/ml represents one of the two maxima of the IL-4
dose/IgGI response curve. This "hyperstimulatory" effect of 600 U/ml of IL-4
is lost if the addition of anti-IL-4 antibody is delayed until day 3; the presence
of this concentration of IL-4 for an additional day causes a marked diminution
in the amount of IgGI produced, to levels below that stimulated by 100 U/ml
IL-4. This suggests that short-term exposure ofBcells to IL-4 leads to heightened
stimulation for IgGI production andthat longer exposure tohigh concentrations
is suppressive.
Distinctive IL-4 Regulation of1gG1 and IgE Production.
￿
The striking diminution
in IgGI production observed when the neutralization of 600 U/ml of IL-4 was
delayed from day 2 to 3 ofculture indicates that the presence ofhigh concentra-
tions of IL-4 "late" in culture is suppressive for IgGI production. To examine
this in greater detail both for IgG1 and IgE production, B cells were cultured
for 2 d with LPS and either 600 or 10,000 U/ml ofIL-4 (Fig. 5). The cells were
then washed and replated at 3 X 10' cells/0.2 ml with LPS and varying IL-4
concentrations. Culture supernatants were removed for measurement of Ig
isotype concentrations after an additional 4 d in culture. B cells cultured with
LPS and 600 U/ml of IL-4 for 2 d produced large amounts of IgGI when
cultured for the remaining 4 d in LPS alone. The addition of up to 37.5 U/ml
ofIL-4 at day 2 had no effect on IgGI production. Higher concentrations ofIL-
4 suppressed IgGI production; the greatest degree of suppression was obtained
at 600 U/ml. 10,000 U/ml, although still suppressive, nonetheless led to the
production ofconsiderably more IgG1 than thatobtained with 600 U/ml during
the second phase of culture. This indicates that very high concentrations of IL-
4 are less suppressive than intermediate concentrations during the final 4 d of
culture.
Culture of B cells with LPS and 10,000 U/ml of IL-4 for the initial 2 d of
culture results in the production ofIgGI in amounts similar to that observed for
cells cultured with 600 U/ml for the first 2 d. Furthermore, cells initiallycultured
with 10,000 U/ml are as sensitive to subsequent suppression by IL-4 as those
initially cultured with 600 U/ml of IL-4. From this experiment, we conclude190
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FIGURE 5. 48-hour preincubation with LPS and high
doses of IL-4. Purified, resting B cells were cultured in
25-cms tissue culture flasks at 2.5 X 105 cells/ml in the
presence of LPS and either 600 (®) or 10,000 (/) U/ml
1L-4 for48 h. Cellswere then washed threetimesin cold
HBSS and replated into 96-well plates at 2 X 10' viable
cells/0.2 ml in the presence of LPS, and increasing con-
centrations of IL-4. Culture supernatants were harvested
4 d after replacing into 96-well plates for determination
of Ig isotypes by ELISA.
that the difference in IgGI production in response to 600 and 10,000 U/ml for
the entire culture period is due to differences in the late "suppressive" period
rather than in the initial "preparatory" period of culture.
Examination ofIgE production in this system revealed that cells prepared with
IL-4 and LPS for 2 d produced very small amounts ofIgE (30-50 ng/ml) at 6 d
when cultured in LPS alone for the final 4 d of culture. The presence of IL-4
during the final 4 d of culture stimulated additional IgE production in a dose-
dependent manner. In contrast to results for IgG1, no suppression is observed;
the amount of IgE produced rises as the concentration of IL-4 present during
the final 4 d ofculture rises, reaching a maximum (>3.5 Ecg/ml) at 10,000 U/ml.
If no IL-4 is present during the initial 2 d of culture, IgE is not produced in
response to addition of even very large amounts of IL-4 during the final 4 d of
culture (data not shown). Thus, the presence of IL-4 with LPS during the initial
2 d ofculture is essential for IgE production. Furthermore, 600 U/ml of IL-4 is
as effective as 10,000 U/ml for this preparatory effect, indicating that the
requirement of very high concentrations of IL-4 to obtain substantial IgE
production reflects a need for such concentrations in the late part ofthe culture.
Discussion
IL-4 is a T cell-derived lymphokine that had been previously shown to
selectively enhance IgGI and IgE production and to suppress IgG3 and IgG2b
secretion by murine B lymphocytes stimulated by LPS (1-6, 12). Initial studies,
while contributing greatly to our knowledge of IL-4-induced regulation of Ig
isotype secretion, were limited by the use ofcrude IL-4-containing supernatants.
More recent studies have used purified T cell-derived or rIL-4 but at relatively
low concentrations. In the current study, we examined the effects of IL-4 overSNAPPER ET AL.
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a much wider concentration range than previously used (up to 10,000 U/ml
[^"50 ng/ml]). This has allowed us to observe several properties of IL-4 in the
regulation of Ig isotype secretion by LPS-stimulated B cells that had not been
previously notedand that maybe ofconsiderable physiologic significance. Among
these are (a) the IL-4-induced increase in IgGI secretion shows a bimodal dose-
response relationship; (6) increasing IL-4 concentrations to 10,000 U/ml causes
a progressive, marked increase in IgE secretion (>5,000-fold enhancement) to
levels >25-fold higher than previously reported; and (c) IL-4 causes a marked
suppressionofIgM and IgG2a secretion as wellasofIgG3 and IgG2b production.
Measurement of cell yields and of [sH]thymidine uptake indicates that both
stimulation of IgGI and IgE and inhibition of Ig of other isotypes cannot be
explained by any general effects on cell proliferation .
Our analysis of both the amounts of IL-4 required and the duration of IL-4
stimulation indicate that control of IgG1 and IgE production is quite distinct.
Optimal IgGI secretion can be achieved by substantially lower concentrations
(^-100-fold) and a shorter time of exposure to IL-4 than that required for high
level IgE secretion.
In light ofstriking changes in Ig isotype secretion at very high IL-4 concentra-
tions, it was important to determine whether these effects were due to IL-4 or
to some possible contaminant. Experiments using the monoclonal anti-IL-4
antibody (11B11) demonstrate unambiguously that IL-4 was critical to all effects
described. Furthermore, using Tcell-derived IL-4 purified by affinity chroma-
tography and reverse-phase HPLC, we observe similar suppression ofIgM, IgG3,
IgG2b, and IgG2a, as well as IgGI and stimulation of IgE at a dose of 1,000
U/ml. The finding that IL-4 obtained from two distinct sources have similar
effectson Ig isotype production and thatthese effects are blocked bymonoclonal
anti-IL-4 antibody indicatesthat the pattern o£regulation observed isan intrinsic
property ofIL-4.
One may question the physiological significance of effects seen at such high
doses of IL-4. It is quite probable that IL-4 can be delivered to its specific
receptor on the B cell surface through intimate physical contact with an IL-4-
secreting T cellin an antigen-specific, histocompatibility-restricted fashion. Kup-
fer et al. have shown that helper T cells align their microtubular-organizing
complex and Golgi apparatus toward the contact surface of a linked antigen-
presenting cell (22). Within the confines of the "synaptic junction" which forms
between interacting T and B cells, it is conceivable that lymphokines could be
"focused" at very high local concentrations at the surface of the antigen-present-
ing B cell surface.
It is ofgreat interest that the same lymphokine, IL-4, controls the expression
of two different Ig isotypes, IgGI and IgE, but that the dose-response curve and
time course for this regulation differ strikingly between the two. IgG1 production
in response to LPS and IL-4 displays a bimodal dose-response curve. The first
peak ofIgG1 production occurs at a concentration ofIL-4 ^"100-fold lower than
that required for maximal IgE secretion; the latter, however, is similar to that
required for the second peak of IgGI production. (The second peak occurs at
the highest IL-4 concentrations used in these experiments and is thus not
necessarily the maximal level that could be achieved. However, in a limited192
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number of experiments, 30,000 U/ml caused substantial cell death, precluding
analysis of the effect of concentrations above 10,000 U/ml). Furthermore, the
inhibition of IgGI production by the addition of IL-4 to B cells that have been
cultured for 2 d with LPS and IL-4 has a complex dose-response curve with
intermediate concentrations (>100 U/ml) showing striking inhibition of IgGI
production but with very high concentrations (10,000 U/ml) actually causing
less inhibition . Although this may reflect IL-4 regulation of a single population
ofprecursors ofIgGI-producing cells, it could also beexplained by the existence
of two populations of precursors of IgGI-producing cells, one stimulated by a
low concentration of IL-4 and inhibited by intermediate to high concentrations
and a second with IL-4 concentration requirements identical to the precursors
of IgE-producing cells. This putative second population of IgGI producers may
also share with the IgE precursors the requirement for a longer duration of
exposure to IL-4 and a failure to be inhibited by late addition of IL-4. Indeed,
it is conceivable that there is a common precursor for the "high-dose IgGI
producers" and for the IgE producers.
The finding that 2-d exposure of B cells to LPS and IL-4 prepares them for
maximal IgGI responses and that concentrations of 600 and 10,000 U/ml are
equally effective for preparation stands in contrast to the dose-dependent inhi-
bition of IgGI production when additional IL-4 is added to these cells after 2 d
of culture. The mechanism underlying the inhibitory effects of "late" IL-4
addition on IgGI production are unknown. A "two-phase" control of IgE
synthesis is also seen, although it is different from the two-phase control of IgGI
production. Incubation of resting B cells with LPS and either 600 or 10,000
U/ml of IL-4 for 2 d prepares these cells, equally well, to secrete large amounts
of IgE if 10,000 U/ml are added to culture after 2 d. Thus, for IgE synthesis,
the initial phase is relatively concentration independent, just as the initial phase
for IgGI production; the late phase requires a high concentration of IL-4 for
IgE production whereas the late presence of IL-4 is inhibitory for IgGI produc-
tion.
The finding that IL-4 controls both IgGI and IgE production is not surprising
since they share important biological properties. Both are capable of binding to
mast cells and mediating degranulation (23) and both are able to mediate
antibody-dependent cellular cytotoxicity by eosinophils for certain parasitic tar-
gets (24, 25). IgE, however, is considerably more efficient for mast cell degran-
ulation (23).
In addition, IL-4 is capable of acting as a costimulant for the growth of mast
cells (26, 27) and upregulates the receptor for the Fc portion of IgE on B cells
(28, 29). It has also been demonstrated that T cell lines, designated TH2 lines,
capable of secreting IL-4 also secrete IL-5 (30, 31; also West, J., F. Carding, R.
Rasmeussen, A. Woods, T. Honjo, and K. Bottomly, manuscript submitted for
publication). IL-5 has been shown to have growth-promoting properties for
eosinophils (32, 33). Finally, it has been recently demonstrated that IL-4 is a
potent costimulant for the growth of multiple hematopoietic precursors (34).
The selective activation ofTH2 cellsby certain parasitic agents, therefore, would
allow for a coordinated host response for parasite elimination that would include
IL-4 and IL-5 release and the stimulation of IgGI and IgE secretion. Further-SNAPPER ET AL.
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more, the suppression ofsecretion ofother isotypes may be important in limiting
the concentrations ofantibodies that compete for antigenic determinants on the
"target" but are unable to initiate an appropriate effector function.
On the other hand, the control of IgGI and IgE are clearly not identical. In
vivo, these Igs occur at vastly different concentrations and the frequencies of
IgGI- and IgE-secreting cells are enormously different (7). Our results indicate
that the regulation of IgGI and IgE production by IL-4 are not the same. The
concentration of IL-4 required to achieve the production of large amounts of
IgE is much greater than concentration of IL-4 that is adequate for striking
stimulation of IgG1 production.
Monoclonal anti-IL-4 antibody strikingly blocks the increase in serum IgE
levels in mice inoculated with the parasitic nematode Nippostrongylus brasiliensis
and in mice stimulated with anti-IgD antibodies while it has little or no effect on
increases in serum IgGI levels (7). This suggests either that larger amounts of
IL-4 are required for IgE than IgGI production in vivo or that IgE production
is exclusively dependent upon IL-4 while IgGI production may be stimulated by
other mechanisms . In either case, the results argue for a differential regulation
of IgGI and IgE production in vivo,just as we have demonstrated for their in
vitro regulation. Other examples of such distinctive regulation are the striking
induction of IgE in helminth-infected mice with only a moderate increase in
IgGI concentrations (7) and the observation that early in the course of rat
schistosomal infections, the predominant protective Ig isotype is the "anaphylac-
tic" rat IgG, IgG2a, while later in the course ofthe disease, protection is mainly
afforded by IgE (35). In view of the very different potencies of murine IgE and
IgGI as anaphylactic antibodies, such distinctive regulation would seem most
appropriate.
Summary
IL-4/B cell stimulatory factor-I is a T cell-derived lymphokine that has been
shown to enhance IgGI and IgE and to suppress IgG3 and IgG2b secretion by
B cells stimulated with bacterial LPS. We show here that the stimulation ofIgGI
and IgE secretion in response to rIL-4 is differentially regulated. The dose-
response curve for IgGI production is bimodal with peaks at 100 and 10,000
U/ml. IgE production is modest at 100 U/ml and exhibits a progressive enhance-
ment as the IL-4 concentration is increased to 10,000 U/ml, reaching ^"1 lAg of
IgE from an initial cell number of 2 X 104. Both of these effects are reversed by
monoclonal anti-IL-4 antibody. Neither the enhancing nor suppressing effects
of IL-4 can be explained by changes in viable cell yields or [sH]thymidine
incorporation. The production of both IgGI and IgE is controlled by IL-4 in a
two-phase manner. During the initial 2 d of culture with LPS, IL-4 action for
both IgGI and IgE production is relatively concentration independent at doses
>600 U/ml. This 2-d treatment leads to maximal IgGI production at day 6 with
no further addition of IL-4. Addition of IL-4 during the final 4 d of culture has
no effect at concentrations under 100 U/ml. At higher concentrations, IL-4 is
strikingly suppressive for IgGI production. By contrast, little IgE is produced
unless IL-4 is present after 2 d ofculture and the response is directly dependent
on the concentration of IL-4 during this second phase of culture with maximal
responses observed at 10,000 U/ml. These differences in IL-4 requirements for194
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IgGl and IgE production, respectively, may have an important role in the
regulation of the synthesis of these isotypes in responses to microbial antigens .
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